Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alefacept in Steroid-Refractory Chronic Graft-versus-Host Disease
NCT01226420Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2010
- Primary completion
- Aug 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of alefacept in chronic graft-versus-host disease (cGVHD), sponsored by Dana-Farber Cancer Institute. Started Oct 2010; status: terminated.
02
Drugs
alefacept
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT01226420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01226420.